Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the
COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the
role of glucose control has been emphasized to improve the prognosis, the impact of
different glucose-lowering agents remains largely unknown. Metformin remains the first-line
pharmacological choice for the management of hyperglycaemia in T2DM. Because
metformin exerts various effects beyond its glucose-lowering action, among which are anti …